Stimulation of tumor necrosis factor-alpha release from lipopolysaccharide-activated human blood monocytes by prostaglandin J2 and metabolites of prostaglandin J2.
Prostaglandin (PG) J2 and related compounds have anti-tumor effects in vivo. To investigate possible mechanisms for this we determined effects of PGD2, PGJ2 and two PGJ2 metabolites delta 12-PGJ2 and 15-deoxy-delta 12, delta 14 PGJ2 on tumor necrosis factor-alpha (TNF-alpha) release from blood monocytes in vitro. All PGJ2 compounds stimulated TNF-alpha-release from lipopolysaccharide-activated monocytes. By contrast, the parent prostaglandin PGD2 had no stimulatory effect. We conclude that the stimulatory effect of PGJ compounds on TNF-alpha formation might contribute to the antineoplastic properties of these compounds.
Vedin
I
I
Former Central Microbiological Laboratory of Stockholm County Council, Sweden.
Wasserman
J
J
Hammarström
S
S
D000970:Antineoplastic Agents / Q000494:pharmacology*; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004008:Diclofenac / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology; D009000:Monocytes / Q000187:drug effects*; D015230:Prostaglandin D2 / Q000031:analogs & derivatives* / Q000494:pharmacology; D011465:Prostaglandins, Synthetic / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D000970:Antineoplastic Agents; D016861:Cyclooxygenase Inhibitors; D008070:Lipopolysaccharides; D011465:Prostaglandins, Synthetic; D014409:Tumor Necrosis Factor-alpha; D004008:Diclofenac; C037112:9-deoxy-delta-9-prostaglandin D2; D015230:Prostaglandin D2